Single nucleotide polymorphisms of the carbonic anhydrase 9 gene are found frequently in patients with metastatic renal cell carcinoma, and predict prognosis and response to immunotherapy.
A diagnosis of diabetes or cardiometabolic disorders was not associated with an increased risk of incident prostate cancer, but rather a decreased incidence of the disease.
Two monoclonal antibodies have demonstrated antitumor activity in clinical trials of men with castrate-resistant prostate cancer.
The temperature spread of blood vessel-sealing devices is limited during radical prostatectomy, meaning that these devices can be used safely for nerve-sparing procedures, provided that the right precautions are taken.
In heavily pretreated men with castration-resistant prostate cancer, a specific and irreversible inhibitor of the enzyme CYP17 promotes declines in levels of PSA and the number of circulating tumor cells and an improvement in performance status.
Major complications detected by computed tomography performed immediately following percutaneous nephrolithotomy are uncommon. However, certain major complications can be detected early.
In a phase II study, about 40% of men with clinically localized, high-risk prostate cancer were free of biochemical recurrence at 18 months when treated with neoadjuvant docetaxel (Taxotere) and ketoconazole followed by surgical excision, according to research presented at the AUA annual meeting.
A single session of high-intensity focused ultrasound as primary therapy for localized prostate cancer results in an acceptable rate of biochemical-free recurrence.
The superiority of nephron-sparing surgery over radical nephrectomy in preserving renal function extends to tumors larger than 4 cm.
Waiting time to nephrectomy is not a predictor of the recurrence of renal cell carcinoma.